DIFFERENCES IN IMMUNE TRANSCRIPTOMIC PROFILE ARE ASSOCIATED WITH RESPONSE TO AZACITIDINE AND VENETOCLAX IN NEWLY DIAGNOSED UNFIT-FOR-CHEMOTHERAPY ACUTE MYELOID LEUKEMIA PATIENTS

被引：0
|
作者：
Zannoni, L. [1 ]
Forte, D. [1 ]
Sartor, C. [1 ]
Cristiano, G. [1 ]
Nanni, J. [1 ]
Parisi, S. [2 ]
Zingarelli, F. [1 ]
Bandini, L. [1 ]
Testoni, N. [1 ]
Ottaviani, E. [2 ]
Paolini, S. [2 ]
Papayannidis, C. [2 ]
Cavo, M. [1 ,3 ]
Rutella, S. [3 ]
Curti, A. [2 ]
机构：
[1] Univ Bologna, Dipartimento Sci Med Chirurg, Bologna, Italy
[2] Univ Bologna, Ist Ematol Seragnoli, IRCCS Azienda Osped, Bologna, Italy
[3] Nottingham Trent Univ, John Geest Canc Res Ctr, Nottingham, England
来源：
HAEMATOLOGICA | 2024年 / 109卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P033
引用
收藏
页码：74 / 75
页数：2
相关论文
共 50 条
  • [1] Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia
    Cherry, Evan M.
    Abbott, Diana
    Amaya, Maria
    McMahon, Christine
    Schwartz, Marc
    Rosser, Julie
    Sato, Audrey
    Schowinsky, Jeffrey
    Inguva, Anagha
    Minhajuddin, Mohd
    Pei, Shanshan
    Stevens, Brett
    Winters, Amanda
    Jordan, Craig T.
    Smith, Clayton
    Gutman, Jonathan A.
    Pollyea, Daniel A.
    BLOOD ADVANCES, 2021, 5 (24) : 5565 - 5573
  • [2] Azacitidine and venetoclax with or without pevonedistat in patients with newly diagnosed acute myeloid leukemia
    Short, Nicholas J.
    Wierzbowska, Agnieszka
    Cluzeau, Thomas
    Laribi, Kamel
    Recher, Christian
    Czyz, Jaroslaw
    Ochrem, Bogdan
    Ades, Lionel
    Gallego-Hernanz, Maria Pilar
    Heiblig, Mael
    Audisio, Ernesta
    Zarzycka, Ewa
    Li, Shuli
    Ferenc, Nicholas
    Yeh, Tammie
    Faller, Douglas V.
    Sedarati, Farhad
    Papayannidis, Cristina
    LEUKEMIA & LYMPHOMA, 2025, 66 (03) : 458 - 468
  • [3] A Randomized Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults with Newly Diagnosed Acute Myeloid Leukemia (AML) Who Are Unfit for Intensive Chemotherapy
    Short, Nicholas J.
    Sedarati, Farhad
    Zhao, Dan
    Tsukurov, Olga
    Friedlander, Sharon
    Faller, Douglas V.
    BLOOD, 2020, 136
  • [4] Real-World Efficacy and Hematologic Toxicity of Azacitidine and Venetoclax in a Cohort of Elderly Patients Unfit for Intensive Chemotherapy With Newly Diagnosed Acute Myeloid Leukemia
    Wysoglad, Hubert
    Krawczyk, Katarzyna
    Ochrem, Bogdan
    Madry, Krzysztof
    Drozd-Sokolowska, Joanna
    Sacha, Tomasz
    Basak, Grzegorz
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S294 - S294
  • [5] Azacitidine Plus Venetoclax for the Treatment of Relapsed and Newly Diagnosed Acute Myeloid Leukemia Patients
    Garciaz, Sylvain
    Hospital, Marie-Anne
    Alary, Anne-Sophie
    Saillard, Colombe
    Hicheri, Yosr
    Mohty, Bilal
    Rey, Jerome
    D'Incan, Evelyne
    Charbonnier, Aude
    Villetard, Ferdinand
    Maisano, Valerio
    Lombardi, Laura
    Ittel, Antoine
    Mozziconacci, Marie-Joelle
    Gelsi-Boyer, Veronique
    Vey, Norbert
    CANCERS, 2022, 14 (08)
  • [6] Combining azole antifungals with venetoclax plus azacitidine in patients with newly diagnosed acute myeloid leukemia
    Zhong, Xushu
    Wang, Jia
    Dai, Yang
    Huang, Xiaoou
    Liu, Jiazhuo
    Xiang, Bing
    Ma, Hongbing
    HEMATOLOGY, 2024, 29 (01)
  • [7] The propriety of upgrading responses to venetoclax plus azacitidine in newly diagnosed patients with acute myeloid leukemia
    Abbott, Diana
    Cherry, Evan
    Amaya, Maria
    McMahon, Christine
    Schwartz, Marc
    Winters, Amanda
    Schowinsky, Jeffrey
    Jordan, Craig T.
    Smith, Clayton
    Gutman, Jonathan A.
    Pollyea, Daniel A.
    LEUKEMIA & LYMPHOMA, 2021, 62 (06) : 1466 - 1473
  • [8] VENETOCLAX, AZACITIDINE, COMBINED WITH LOW-DOSE CYTARABINE IMPROVE THE REMISSION RATE IN OLDER OR UNFIT PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA
    Han, Xiao
    Song, Qingxiao
    Wan, Kai
    Zhang, Mengyun
    Liu, Xue
    Yan, Hongju
    Zhang, Cheng
    Wen, Qin
    Zhang, Xi
    BONE MARROW TRANSPLANTATION, 2024, 59 : 176 - 177
  • [9] A Systematic Review of Venetoclax and Azacitidine: Effectiveness and Safety for Newly Diagnosed and Relapsed Acute Myeloid Leukemia Patients
    Ibrahim, Ahmed
    Yousaf, Muhammad Abdullah
    Anwar, Zain
    Anum
    Batool, Maha
    Rehman, Mohammad
    Safdar, Omar A.
    Khattak, Zeeshan Ahmed
    Faraz, Fatima
    Khalid, Huma
    BLOOD, 2023, 142
  • [10] Single-institution experience of venetoclax combined with azacitidine in newly diagnosed acute myeloid leukemia patients
    Yu, Hong
    Wang, Chaomeng
    Lei, Yingying
    Li, Lijuan
    Wang, Huaquan
    Wang, Guojin
    Xing, Limin
    Guan, Jing
    Song, Jia
    Wu, Yuhong
    Liu, Hong
    Qu, Wen
    Wang, Xiaoming
    Shao, Zonghong
    Fu, Rong
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 127
12345